Regeneron

News

COPD patients will get access to Dupixent via NHS

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

News

China clears GSK's Nucala for COPD

GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.

News

Spokesman from MD Anderson Cancer Center

ASH: Regeneron makes frontline case for Lynozyfic in myeloma

Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

R&D

Interview at LSX 25 with Alison Fenney feature

Why Regeneron is giving away sequencing “for free”, with Ali...

Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.

COPD patients will get access to Dupixent via NHS

China clears GSK's Nucala for COPD

ASH: Regeneron makes frontline case for Lynozyfic in myeloma

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Regeneron's Libtayo stakes out new territory in skin cancer

Why Regeneron is giving away sequencing “for free”, with Ali...

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Regeneron

Editor's Picks